RU2020123241A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020123241A3 RU2020123241A3 RU2020123241A RU2020123241A RU2020123241A3 RU 2020123241 A3 RU2020123241 A3 RU 2020123241A3 RU 2020123241 A RU2020123241 A RU 2020123241A RU 2020123241 A RU2020123241 A RU 2020123241A RU 2020123241 A3 RU2020123241 A3 RU 2020123241A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762599583P | 2017-12-15 | 2017-12-15 | |
US62/599,583 | 2017-12-15 | ||
US201862678891P | 2018-05-31 | 2018-05-31 | |
US62/678,891 | 2018-05-31 | ||
PCT/US2018/065817 WO2019118909A1 (en) | 2017-12-15 | 2018-12-14 | Polycyclic compounds as allosteric shp2 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2020123241A RU2020123241A (ru) | 2022-01-17 |
RU2020123241A3 true RU2020123241A3 (ru) | 2022-03-31 |
Family
ID=65003535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020123241A RU2020123241A (ru) | 2017-12-15 | 2018-12-14 | Полициклические соединения в качестве аллостерических ингибиторов shp2 |
Country Status (16)
Country | Link |
---|---|
US (2) | US11673901B2 (ru) |
EP (1) | EP3724189B1 (ru) |
JP (1) | JP7361693B2 (ru) |
KR (1) | KR20200099530A (ru) |
CN (1) | CN111433205B (ru) |
AU (1) | AU2018385713A1 (ru) |
BR (1) | BR112020009757A2 (ru) |
CA (1) | CA3084058A1 (ru) |
CO (1) | CO2020005887A2 (ru) |
IL (1) | IL275089A (ru) |
MX (1) | MX2020006273A (ru) |
PH (1) | PH12020550857A1 (ru) |
RU (1) | RU2020123241A (ru) |
SG (1) | SG11202004090YA (ru) |
TW (1) | TW201927791A (ru) |
WO (1) | WO2019118909A1 (ru) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
CN109415360B (zh) | 2016-06-14 | 2021-11-02 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
EP4302834A2 (en) | 2016-07-12 | 2024-01-10 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
BR112019015075A2 (pt) | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
SG11202001282UA (en) | 2017-09-07 | 2020-03-30 | Revolution Medicines Inc | Shp2 inhibitor compositions and methods for treating cancer |
EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
CA3084058A1 (en) | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
CN110655520A (zh) * | 2018-06-29 | 2020-01-07 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
CN115448923B (zh) * | 2018-02-13 | 2024-03-22 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
EP3753941B1 (en) * | 2018-02-13 | 2024-05-01 | Shanghai Blueray Biopharma Co., Ltd. | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
IL276232B2 (en) | 2018-03-02 | 2024-04-01 | Otsuka Pharma Co Ltd | History of pyrazine, pharmaceutical compounds containing them and their use in the treatment of diseases |
WO2019183367A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2019213318A1 (en) | 2018-05-02 | 2019-11-07 | Board Of Regents, The University Of Texas System | Substituted heterocyclic inhibitors of ptpn11 |
MA53395A (fr) * | 2018-07-24 | 2021-06-02 | Otsuka Pharma Co Ltd | Composés hétérobicycliques pour inhiber l'activité de shp2 |
KR20210043569A (ko) | 2018-08-10 | 2021-04-21 | 나비레 파르마, 인코퍼레이티드 | 암 치료를 위한 ptpn11 (shp2) 저해제로서 6-(4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일)-3-(2,3-디클로로페닐)-2-메틸피리미딘-4(3h)-온 유도체 및 관련 화합물 |
KR20210060556A (ko) | 2018-09-18 | 2021-05-26 | 니캉 테라퓨틱스 인코포레이티드 | Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체 |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
CN117143079A (zh) | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
CN111153901B (zh) * | 2018-11-07 | 2022-01-25 | 上海凌达生物医药有限公司 | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 |
TW202039498A (zh) * | 2018-11-30 | 2020-11-01 | 大陸商上海拓界生物醫藥科技有限公司 | 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
CA3127361A1 (en) | 2019-03-07 | 2020-09-10 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as shp2 antagonists |
CN113874363A (zh) | 2019-04-02 | 2021-12-31 | Array生物制药公司 | 蛋白质酪氨酸磷酸酶抑制剂 |
AU2020271838A1 (en) | 2019-04-08 | 2021-08-19 | Merck Patent Gmbh | Pyrimidinone derivatives as SHP2 antagonists |
BR112021024674A2 (pt) * | 2019-06-28 | 2022-05-31 | Tuojie Biotech Shanghai Co Ltd | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo |
CN111704611B (zh) * | 2019-07-25 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类芳基螺环类shp2抑制剂化合物、制备方法和用途 |
CN112300160A (zh) * | 2019-08-01 | 2021-02-02 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物、其制备及应用 |
EP3772513A1 (en) | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
CN112574212B (zh) * | 2019-09-30 | 2022-04-19 | 上海拓界生物医药科技有限公司 | 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
CN110790711A (zh) * | 2019-11-29 | 2020-02-14 | 都创(上海)医药科技有限公司 | 一种2-氯-4-氨基-6-甲基嘧啶化合物制备方法 |
CN113004282B (zh) * | 2019-12-19 | 2024-05-24 | 首药控股(北京)股份有限公司 | 取代的炔基杂环化合物 |
WO2021121397A1 (zh) * | 2019-12-19 | 2021-06-24 | 首药控股(北京)股份有限公司 | 取代的炔基杂环化合物 |
WO2021171261A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
CN115279749B (zh) * | 2020-04-30 | 2024-05-10 | 贝达药业股份有限公司 | Shp2抑制剂及其组合物和应用 |
CN115515946A (zh) * | 2020-06-11 | 2022-12-23 | 贝达药业股份有限公司 | Shp2抑制剂及其组合物和应用 |
CN115515947B (zh) * | 2020-07-24 | 2024-02-06 | 贝达药业股份有限公司 | Shp2抑制剂及其组合物和应用 |
CN116724042A (zh) * | 2020-08-10 | 2023-09-08 | 深圳微芯生物科技股份有限公司 | 一种杂三环类化合物及其制备方法和应用 |
WO2022135568A1 (zh) * | 2020-12-25 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 一种嘧啶并五元氮杂环类衍生物的晶型及其制备方法 |
EP4039685A1 (en) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
EP4067358A1 (en) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023109761A1 (zh) * | 2021-12-15 | 2023-06-22 | 贝达药业股份有限公司 | 吡唑并嘧啶酮类化合物及其盐的结晶 |
TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek抑制劑及其用途 |
EP4345101A1 (en) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2572728A (en) | 1949-01-07 | 1951-10-23 | American Cyanamid Co | Hydroxybenzenesulfonamidopyra-zines and preparation of same |
US2636882A (en) | 1950-08-11 | 1953-04-28 | Quaker Oats Co | Preparation of 3-pyridols from 2-acylfurans |
BE758503A (fr) | 1969-11-07 | 1971-05-05 | Shell Int Research | Compositions pesticides |
GB1459571A (en) | 1974-09-12 | 1976-12-22 | Pfizer Ltd | Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus |
JPS5762269A (en) | 1980-10-03 | 1982-04-15 | Ogawa Koryo Kk | 2,3,5-trisubstituted pyrazine derivative |
US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
DE3242195A1 (de) | 1982-11-15 | 1984-05-17 | Basf Ag, 6700 Ludwigshafen | Neue 2-aminopyrazine und verfahren zur herstellung von 2-aminopyrazinen und pyrazinen |
JPH0249775A (ja) | 1988-05-19 | 1990-02-20 | Nippon Soda Co Ltd | 6員環又は7員環を有する複素環化合物及びその製造方法 |
JPH04112877A (ja) | 1990-09-04 | 1992-04-14 | Nippon Soda Co Ltd | 新規シアノピラジン誘導体及びその製造方法 |
WO1993009664A1 (en) | 1991-11-12 | 1993-05-27 | Nippon Soda Co., Ltd. | Wavelength conversion material for agriculture |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
GB9504854D0 (en) | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
DE69736513T2 (de) | 1996-02-07 | 2007-04-05 | Neurocrine Biosciences, Inc., San Diego | Pyrazolopyrimidine als crf rezeptor-antagonisten |
JP2002512628A (ja) | 1997-06-13 | 2002-04-23 | スージェン・インコーポレーテッド | タンパク質チロシン酵素関連の細胞信号伝達を調節するための新規ヘテロアリール化合物 |
JP2003508382A (ja) | 1999-08-27 | 2003-03-04 | スージェン・インコーポレーテッド | リン酸模倣体およびホスファターゼ阻害剤を用いる治療方法 |
US6995161B2 (en) | 2000-02-16 | 2006-02-07 | Neurogen Corporation | Substituted arylpyrazines |
US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
CA2467870A1 (en) | 2001-11-21 | 2003-06-05 | Pharmacia & Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
CA2479744A1 (en) | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
AU2003269949A1 (en) | 2002-09-12 | 2004-04-30 | Pharmacia & Upjohn Company Llc | Substituted 1,4-pyrazine derivatives |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
MXPA05012082A (es) | 2003-05-09 | 2006-02-22 | Pharmacia & Upjohn Co Llc | Compuestos como antagonistas del receptor crf1. |
GB0314057D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
EP1675858A2 (en) | 2003-09-03 | 2006-07-05 | Neurogen Corporation | 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds |
WO2005035532A1 (en) | 2003-10-10 | 2005-04-21 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
RU2006118325A (ru) | 2003-10-27 | 2007-12-10 | Астеллас Фарма Инк. (Jp) | Производные пиразина и их фармацевтическое применение |
DE102004015954A1 (de) | 2004-04-01 | 2005-11-10 | Ina-Schaeffler Kg | Umschlingungstrieb |
CN1938296A (zh) | 2004-04-01 | 2007-03-28 | 安斯泰来制药有限公司 | 作为腺苷拮抗剂的吡嗪衍生物及其制药用途 |
US20050282818A1 (en) | 2004-06-22 | 2005-12-22 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
ATE466000T1 (de) | 2004-12-23 | 2010-05-15 | Mallinckrodt Inc | Fluoreszente pyrazinderivate und verfahren zu deren anwendung bei der bewertung der nierenfunktion |
WO2006113704A2 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
EP1893612B1 (en) | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
EP1948827B1 (en) | 2005-10-21 | 2016-03-23 | The Regents of The University of California | C-kit oncogene mutations in melanoma |
EP1986701B1 (en) | 2006-02-24 | 2012-06-13 | Mallinckrodt LLC | Optical agents for use in surgery |
JP2007277097A (ja) | 2006-04-03 | 2007-10-25 | Mie Univ | 発光化合物、発光方法、及びその製造方法 |
WO2007117699A2 (en) | 2006-04-07 | 2007-10-18 | University Of South Florida | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs |
US20100168120A1 (en) | 2006-04-28 | 2010-07-01 | Neuromedix Inc. | Salts of pyridazine compounds |
CN101754762A (zh) | 2006-04-28 | 2010-06-23 | 西北大学 | 用于治疗神经炎症性疾病的包含哒嗪化合物的制剂 |
US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
CA2653506A1 (en) | 2006-05-31 | 2007-12-06 | Galapagos Nv. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
CA2654202A1 (en) | 2006-06-06 | 2007-12-21 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
CN101622652B (zh) | 2007-02-08 | 2012-03-21 | 行为识别系统公司 | 行为识别系统 |
ES2363831T3 (es) | 2007-04-06 | 2011-08-17 | Novartis Ag | [2,6]naftiridinas útiles como inhibidores de quinasas proteínicas. |
US8133895B2 (en) | 2007-05-10 | 2012-03-13 | Janssen Pharmaceutica N.V. | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
WO2008138842A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
JPWO2008156174A1 (ja) | 2007-06-21 | 2010-08-26 | 大正製薬株式会社 | ピラジンアミド化合物 |
EP2184981A4 (en) | 2007-08-09 | 2012-02-01 | Merck Sharp & Dohme | PYRIDINECARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS |
WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
US8703770B2 (en) | 2008-10-30 | 2014-04-22 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
US8324200B2 (en) | 2009-01-23 | 2012-12-04 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
EP2438041A4 (en) | 2009-06-01 | 2012-11-21 | Merck Sharp & Dohme | PYRAZINE-carboxamide-orexin receptor Antagonist |
KR101906146B1 (ko) | 2009-08-17 | 2018-10-10 | 메모리얼 슬로안-케터링 캔서 센터 | 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법 |
AU2010291835A1 (en) | 2009-09-03 | 2012-04-19 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
TW201200518A (en) * | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
WO2011143148A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
SG186989A1 (en) | 2010-07-14 | 2013-02-28 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
WO2012149280A2 (en) * | 2011-04-29 | 2012-11-01 | Abbott Laboratories | Novel tricyclic compounds |
CN103181918B (zh) | 2011-05-04 | 2014-10-29 | 厦门大学 | 脂肪酸类化合物在制备预防和治疗肝癌药物中的应用 |
US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
ES2618004T3 (es) | 2012-08-07 | 2017-06-20 | Merck Patent Gmbh | Derivados de piridopirimidina como inhibidores de proteínas quinasas |
CA2890009C (en) | 2012-11-08 | 2017-11-28 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
BR112015012366A8 (pt) | 2012-11-29 | 2019-10-01 | Chemocentryx Inc | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido |
US20150352131A1 (en) | 2013-01-16 | 2015-12-10 | Rhode Island Hospital | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis |
AU2014214326B2 (en) | 2013-02-07 | 2018-07-05 | Prexton Therapeutics Sa | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mGluR4 |
RU2019137208A (ru) | 2013-02-20 | 2020-02-19 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
CN103554038B (zh) | 2013-06-19 | 2015-10-14 | 云南大学 | 多卤代苯腈喹唑啉酮化合物及其制备方法和用途 |
CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
US11331312B2 (en) | 2014-04-25 | 2022-05-17 | Memorial Sloan-Kettering Cancer Center | Treatment of H-Ras-driven tumors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US10752640B2 (en) | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
CA2967944C (en) | 2014-11-18 | 2020-11-17 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with a2a antagonist properties |
WO2016100116A1 (en) | 2014-12-17 | 2016-06-23 | Siemens Healthcare Diagnostics Inc. | Sandwich assay design for small molecules |
DK3237418T3 (da) | 2014-12-23 | 2019-05-13 | Novartis Ag | Triazolopyrimidinforbindelser og anvendelser deraf |
EP3247378B8 (en) | 2015-01-09 | 2023-08-23 | Revolution Medicines, Inc. | Macrocyclic compounds that participate in cooperative binding and medical uses thereof |
WO2016125169A1 (en) | 2015-02-05 | 2016-08-11 | Tyrnovo Ltd. | Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer |
JP6995623B2 (ja) * | 2015-04-03 | 2022-01-14 | インサイト・コーポレイション | Lsd1阻害剤としてのヘテロ環式化合物 |
EP3310774B1 (en) | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
US10426842B2 (en) | 2015-07-15 | 2019-10-01 | The Curators Of The University Of Missouri | Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug |
JP7411326B2 (ja) | 2015-10-01 | 2024-01-11 | ワープ ドライブ バイオ インコーポレイテッド | タンパク質-タンパク質インターフェースを分析するための方法および試薬 |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
CA3026784A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
CN109415360B (zh) | 2016-06-14 | 2021-11-02 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
EP4302834A2 (en) | 2016-07-12 | 2024-01-10 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
ES2964956T3 (es) | 2017-01-10 | 2024-04-10 | Novartis Ag | Combinación farmacéutica que comprende un inhibidor de ALK y un inhibidor de SHP2 |
BR112019015075A2 (pt) * | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
KR20210130254A (ko) | 2017-03-23 | 2021-10-29 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
KR20240033100A (ko) | 2017-04-05 | 2024-03-12 | 레볼루션 메디슨즈, 인크. | 협동 결합에 참여하는 화합물 및 그의 용도 |
EP3607326A4 (en) | 2017-04-05 | 2020-11-18 | Revolution Medicines, Inc. | METHODS AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
SG11202001282UA (en) | 2017-09-07 | 2020-03-30 | Revolution Medicines Inc | Shp2 inhibitor compositions and methods for treating cancer |
SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
CA3084058A1 (en) | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
CN115448923B (zh) * | 2018-02-13 | 2024-03-22 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
EP3753941B1 (en) | 2018-02-13 | 2024-05-01 | Shanghai Blueray Biopharma Co., Ltd. | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
CN112368272B (zh) | 2018-03-21 | 2023-04-21 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
KR20200143417A (ko) | 2018-04-10 | 2020-12-23 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법 |
CR20200578A (es) | 2018-05-01 | 2021-02-22 | Revolution Medicines Inc | Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor |
CN112368289B (zh) | 2018-05-01 | 2024-02-20 | 锐新医药公司 | 作为mtor抑制剂的c26-连接的雷帕霉素类似物 |
WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
KR20210060556A (ko) | 2018-09-18 | 2021-05-26 | 니캉 테라퓨틱스 인코포레이티드 | Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체 |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
CN113473990A (zh) | 2018-10-08 | 2021-10-01 | 锐新医药公司 | 用于治疗癌症的shp2抑制剂组合物 |
CN111153901B (zh) * | 2018-11-07 | 2022-01-25 | 上海凌达生物医药有限公司 | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
US20220073521A1 (en) | 2018-11-30 | 2022-03-10 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof |
TW202039498A (zh) * | 2018-11-30 | 2020-11-01 | 大陸商上海拓界生物醫藥科技有限公司 | 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
CA3123869A1 (en) | 2018-12-21 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
-
2018
- 2018-12-14 CA CA3084058A patent/CA3084058A1/en active Pending
- 2018-12-14 CN CN201880079071.1A patent/CN111433205B/zh active Active
- 2018-12-14 KR KR1020207017257A patent/KR20200099530A/ko not_active Application Discontinuation
- 2018-12-14 MX MX2020006273A patent/MX2020006273A/es unknown
- 2018-12-14 TW TW107145128A patent/TW201927791A/zh unknown
- 2018-12-14 WO PCT/US2018/065817 patent/WO2019118909A1/en active Search and Examination
- 2018-12-14 RU RU2020123241A patent/RU2020123241A/ru unknown
- 2018-12-14 EP EP18830634.4A patent/EP3724189B1/en active Active
- 2018-12-14 SG SG11202004090YA patent/SG11202004090YA/en unknown
- 2018-12-14 JP JP2020531962A patent/JP7361693B2/ja active Active
- 2018-12-14 AU AU2018385713A patent/AU2018385713A1/en not_active Abandoned
- 2018-12-14 BR BR112020009757-8A patent/BR112020009757A2/pt not_active Application Discontinuation
-
2020
- 2020-05-14 CO CONC2020/0005887A patent/CO2020005887A2/es unknown
- 2020-06-03 IL IL275089A patent/IL275089A/en unknown
- 2020-06-10 PH PH12020550857A patent/PH12020550857A1/en unknown
- 2020-06-11 US US16/899,446 patent/US11673901B2/en active Active
-
2023
- 2023-02-17 US US18/111,453 patent/US20240101577A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200099530A (ko) | 2020-08-24 |
EP3724189B1 (en) | 2023-10-04 |
JP2021506776A (ja) | 2021-02-22 |
CN111433205B (zh) | 2024-01-19 |
BR112020009757A2 (pt) | 2020-11-03 |
TW201927791A (zh) | 2019-07-16 |
RU2020123241A (ru) | 2022-01-17 |
EP3724189A1 (en) | 2020-10-21 |
WO2019118909A1 (en) | 2019-06-20 |
PH12020550857A1 (en) | 2021-05-17 |
CO2020005887A2 (es) | 2020-08-10 |
CN111433205A (zh) | 2020-07-17 |
MX2020006273A (es) | 2020-09-14 |
US20200407372A1 (en) | 2020-12-31 |
CA3084058A1 (en) | 2019-06-20 |
US11673901B2 (en) | 2023-06-13 |
US20240101577A1 (en) | 2024-03-28 |
IL275089A (en) | 2020-07-30 |
SG11202004090YA (en) | 2020-05-28 |
JP7361693B2 (ja) | 2023-10-16 |
AU2018385713A1 (en) | 2020-06-18 |